Randomized Clinical Study Shows Ultra Glucose Control® in Combination with a Dietary Plan Results in a Significant Reduction in A1C Levels and Body Weight in Overweight and Obese Patients with Type 2 Diabetes

Study results presented at American Diabetes Association's 76th Scientific Sessions

News provided by

Jun 13, 2016, 04:00 ET

ALISO VIEJO, Calif., June 13, 2016 /PRNewswire/ -- Metagenics, Inc., a lifestyle functional nutrition company, today announced novel clinical results of a randomized controlled research study that shows Ultra Glucose Control^® Medical Food in combination with a dietary plan results in significant reduction in A1C levels and body weight in overweight and obese patients with Type 2 Diabetes compared to an individualized dietary plan alone. The study, conducted by the Joslin Diabetes Center, was presented yesterday at the American Diabetes Association's 76^th Scientific Sessions in New Orleans, Louisiana.

"Effective management of A1C levels, while challenging, is critical to reducing the risk of diabetes-related complications," said Osama Hamdy, M.D., Ph.D., FACE, medical director of the Obesity Clinical Program and director of the Inpatient Diabetes Program at the Joslin Diabetes Center. "This data is encouraging, as overweight adults with Type 2 diabetes now have a more effective approach to reducing A1C and body weight through a structured dietary plan that includes Ultra Glucose Control."

The study compared the effect of three Medical Nutrition Therapy models on A1C and body weight in 108 overweight and obese adults with uncontrolled Type 2 diabetes randomized into 3 equal groups over a period of 16 weeks. Group A met with a registered dietitian (RD) to develop individualized eating plans; Group B met with an RD to receive a structured meal plan that includes menu books, keeping a food log, and using 1-3 servings of Ultra Glucose Control^® per day as calorie replacements; and Group C followed a plan similar to Group B in addition to receiving weekly phone coaching by RD. Compared to baseline, A1C did not change in Group A while significantly decreasing in Groups B (-0.63±0.18%, p<0.001) and C (-0.67±0.19%, p<0.001). Change in A1C was significantly different between groups (p=0.0006). Body weight non-significantly decreased in Group A, but significantly decreased in Group B (-3.49±0.73 kg, p<0.001) and Group C (-2.73±0.78 kg, p<0.001).

This study follows another recent study conducted by the Joslin Diabetes Center evaluating glucose and insulin response to oatmeal versus commercially available diabetes-specific formulas. The study's findings demonstrated that Ultra Glucose Control^® delivered a sustained and significantly lower glucose response over 4 hours that was superior to other commercially available formulas.

ABOUT THE STUDY

Effects of 3 Different Models of Medical Nutrition Therapy on A1C and Body Weight in Overweight and Obese Patients with Type 2 Diabetes: A Randomized Clinical Study (NCT02520050)

In this clinical study, the effect of 3 different models of medical nutrition therapy (MNT) on A1C and body weight over 16 weeks was evaluated. One hundred and eight overweight and obese adults with T2D (46M / 62F; age 60±10 years; A1C 8.07±1.05%; weight 101.4±21.1 kg and BMI 35.2±7.7 kg/m²) not treated with insulin were randomized to one of three groups. Group A— met with a registered dietitian (RD) to develop individualized eating plans; Group B— met with a RD to receive a structured meal plan that includes menu books, keeping a food log, and using a medical food (Ultra Glucose Control^®); and Group C—followed a plan similar to Group B in addition to receiving weekly coaching from a RD over the phone. Diabetes medications were stable throughout the study unless a participant reported hypoglycemia.

Compared to baseline, A1C did not change in Group A while decreasing in Groups B (-0.63±0.18%, p<0.001) and C (-0.67±0.19%, p<0.001). Change in A1C was significantly different between groups (p=0.0006). Body weight did not change in Group A while decreasing significantly in Groups B (-3.49±0.73 kg, p<0.001) and group C (-2.73±0.78 kg, p<0.001). Weight reduction was not different between the 3 groups.

To find an authorized Metagenics healthcare practitioner, or for more information about Ultra Glucose Control, visit www.Metagenics.com.

About Metagenics, Inc.
Metagenics, Inc. (www.metagenics.com) is a Lifestyle Functional Nutrition company dedicated to helping people live happier, healthier lives by realizing their genetic potential. Founded in 1983, Metagenics serves more than 75,000 healthcare providers worldwide through premium quality, science-based medical foods, nutritional formulas, and lifestyle therapy programs such as FirstLine Therapy to help their patients achieve a lifetime of good health. Metagenics' scientific staff—among the largest in the industry—has published more than 80 articles in peer-reviewed journals and has been awarded more than 50 patents in the USA and around the globe. The company collaborates with renowned medical experts to annually deliver more than 200 events designed to help healthcare professionals stay on the leading edge of lifestyle medicine and incorporate nutrition into their clinical practice.

Metagenics maintains its corporate headquarters in Aliso Viejo, CA; R&D headquarters in Gig Harbor, WA; and operating subsidiaries in Brussels, Belgium, and Australia.

Media contact:
Colleen O'Malley
[email protected]
312-396-9707

SOURCE Metagenics, Inc.